Neuropharmacology Core

项目总结/摘要 自然产品神经科学卓越研究中心（CORE-NPN） 密西西比药学院（UM），十年前通过COBRE赠款发起，已经开发了一种 致力于评估天然产品对中枢神经系统的影响的多学科团队 （CNS）。COBRE CORE-NPN计划的神经药理学研究核心代表了一个共享的 为生物医学研究者/用户提供神经药理学专业服务和培训的资源 基于（a）竞争性放射性配体受体结合，（B）分子/生物化学靶点调节的生物测定 功能（c）基于细胞的表型和功能反应和（d）体内行为药理学。这是 最初有两个核心，体外和体内药理学，I期和II期，研究者使用率很高 两者之间的紧密合作。在第三阶段，已经确定这些核心将最好地服务于 程序作为一个功能单元。此外，到第三阶段结束时，核心项目预计将基本上 可持续性，重点是了解铅生物提取物的神经药理学特性， 纯化的化合物以及它们如何与生物系统相互作用。努力的重点是扩大 通过增加可供用户使用的体外和体内试验，从而提高 服务的预计用户数。将在2010年期间实施按服务收费/按存储容量使用计费的业务模式。 第三阶段：确保第三阶段后的可持续性。特定的核心服务包括放射性配体结合和功能性 大麻素、阿片样物质和神经肽FF G蛋白偶联受体（GPCR）以及酶 分析、基于表型神经元细胞培养的分析和神经药理学信号传导分析 途径。此外，核心提供了一系列急性行为啮齿动物和斑马鱼测定，以评估 天然产物提取物和纯化的化合物在体内。新的体外试验和动物模型将继续 这将有助于开发一个新的核心框架，以支持用户需求，最终扩大核心的总体范围和用户基础。 核心的定位是成为一个领导者，在神经药理学服务的基础上，天然产品和 合成药物开发运动。我们计划通过以下具体目标来实现这一目标： 通过最先进的技术，加强COBRE CORE-NPN和相关社区的研究 设备，尖端技术和科学专业知识; 2）推进发展的基础设施 服务，以促进COBRE核心-NPN研究和相关的社区，通过不断完善和 通过用户输入添加测定。3)通过以下方式加快核心可持续性的长期计划： 扩大用户基础，整合收费服务结构，机构支持， 通过监测用户的需求来改变。

PROJECT SUMMARY/ABSTRACT The Center of Research Excellence in Natural Products Neuroscience (CORE-NPN) at The University of Mississippi School of Pharmacy (UM), initiated ten years ago through a COBRE grant, has developed a multidisciplinary team committed to evaluating the effects of natural products on the central nervous system (CNS). The Neuropharmacology Research Core of the COBRE CORE-NPN program represents a shared resource serving biomedical investigators / users with specialized services and training in neuropharmacological bioassays based on (a) competitive radioligand receptor binding, (b) modulation of molecular/biochemical target functions (c) cell-based phenotypic & functional responses and (d) in vivo behavioral pharmacology. This was originally two Cores, in vitro and in vivo pharmacology, in Phases I and II, with strong utilization by investigators and strong collaboration between the two. In Phase III, it has been determined that these Cores would best serve the program as one functional unit. Furthermore, by the end of Phase III, the Core is projected to be largely sustainable with efforts focused on understanding neuropharmacological properties of lead biological extracts or purified compounds and how they interact with biological systems. Efforts have been focused on expanding the core capabilities by increasing both in vitro and in vivo assays that are available to users, thereby increasing the numbers of projected users served. A fee-for-service/chargeback business model will be implemented during Phase III to ensure sustainability post Phase III. Specific Core services include radioligand binding and functional assays for cannabinoid, opioid, and Neuropeptide FF G protein-coupled receptors (GPCRs), as well as enzyme assays, phenotypic neuronal cell cultures-based assays, and analysis of neuropharmacological signaling pathways. Moreover, the Core offers a battery of acute behavioral rodent and zebrafish assays to evaluate natural product extracts and purified compounds in vivo. New in vitro assays and animal models will continue to be developed to support user needs, which ultimately broadens the overall scope and user-base for the Core. The Core is positioned to become a leader in neuropharmacological services based on natural product and synthetic drug development campaigns. We plan to achieve this through the following Specific Aims: 1) To enhance the research of the COBRE CORE-NPN and the associated community through state-of-the-art equipment, cutting-edge techniques, and scientific expertise; 2) To advance an infrastructure of developmental services to facilitate COBRE CORE-NPN research and the associated community by continual refinement and addition of assays through user input. 3) To accelerate a long-term plan for sustainability of the Core through expansion of the user base, integration of a fee-for-service structure, institutional support, and adaptation to changes by monitoring the needs of the users.